Found 31 articles for: "scar"
JAK/STAT Inhibitors Reduce Risk of New-Onset Keloids and Hypertrophic Scars: A Multi-Center Retrospective Cohort Study
September 2026 | Volume 25 | Issue 9 | Original Article | 779 | Copyright © September 2026
Background: Keloids and hypertrophic scars are fibroproliferative skin disorders characterized by excessive collagen deposition and high recurrence rates despite existing therapi...
Read MoreEyebrow Madarosis: An Updated Review of the Etiology and Management, Part II– Scarring Disorders
September 2026 | Volume 25 | Issue 9 | Original Article | 852 | Copyright © September 2026
Background: Eyebrows play an essential role in facial symmetry, communication, and aesthetic identity. Scarring eyebrow alopecia results from inflammatory, autoimmune, infectious...
Read MoreStandardized Suture Tail Cutting Technique for Enhanced Cosmesis in Epidermal Closure
September 2026 | Volume 25 | Issue 9 | Editorials | e83 | Copyright © September 2026
Current Considerations for Laser and Energy-Based Devices in Transgender Patient Care
September 2026 | Volume 25 | Issue 9 | Features | 881 | Copyright © September 2026
Alopecia Areata in Children and the Emerging Role of JAK Inhibitors
July 2026 | Volume 25 | Issue 7 | Features | e61 | Copyright © July 2026
Racial Differences in Secondary Skin Complications and Timing of Topical Therapy Initiation for Pseudofolliculitis Barbae: A Multicenter Retrospective Database Cohort Study
July 2026 | Volume 25 | Issue 7 | Editorials | e69 | Copyright © July 2026
Treating Acne Vulgaris and Scarring With Botulinum Toxin: A Systematic Review
June 2026 | Volume 25 | Issue 6 | Original Article | 508 | Copyright © June 2026
Background: Many treatments have been proposed for the treatment of acne vulgaris and acne scarring; however, few data exist regarding the efficacy of botulinum toxin A as a trea...
Read MorePersistent Alopecic Patches Following Dutasteride Mesotherapy for Female Androgenetic Alopecia: A Case Series
March 2026 | Volume 25 | Issue 3 | Original Article | 951 | Copyright © March 2026
Background: Androgenetic alopecia (AGA) is the most common cause of hair loss. To minimize systemic adverse effects of 5-alpha-reductase inhibitors, dutasteride mesotherapy has g...
Read MorePatient Perspectives and Attitudes Toward the Diagnostic Process for Central Centrifugal Cicatricial Alopecia
March 2026 | Volume 25 | Issue 3 | Features | 282 | Copyright © March 2026
A Decade of Hair Prosthetic Injuries: A Review of United States Emergency Department Cases (2013-2022)
March 2026 | Volume 25 | Issue 3 | Features | 277 | Copyright © March 2026
Treatment Strategy for Refractory Dissecting Cellulitis of the Scalp Using Bimekizumab, Isotretinoin, and Oral Antibiotics
March 2026 | Volume 25 | Issue 3 | Case Reports | 275 | Copyright © March 2026
Dissecting cellulitis of the scalp (DCS) is a chronic inflammatory disorder of the scalp that manifests as inflamed nodules and abscesses, with subsequent patchy, scarring hair loss. While its ex...
Read MoreScar Wars: A Review of Topical Scar Therapies
December 2025 | Volume 24 | Issue 12 | Features | 1265 | Copyright © December 2025
Elevated Atherosclerotic Cardiovascular Disease Risk in Fibrotic Skin Diseases: Insights From a TriNetX Cohort Study
November 2025 | Volume 24 | Issue 11 | Original Article | 1121 | Copyright © November 2025
Background: Identifying the risk of atherosclerotic cardiovascular disease (ASCVD) is a cornerstone of preventive medical care. Despite its significance, limited research has exp...
Read MoreAnalysis of Therapeutic Interventions for Hypertrophic and Keloid Scarring: A Systematic Review
August 2025 | Volume 24 | Issue 8 | Original Article | 770 | Copyright © August 2025
This systematic review compares the efficacy of pressure garment therapy (PGT) and non-PGT treatments, such as triamcinolone, verapamil, and laser therapies, for hypertrophic and keloid scars. Fo...
Read MoreClindamycin Phosphate 1.2%/Adapalene 0.15%/ Benzoyl Peroxide 3.1% for Acne: Results From A 6-Month Open-Label Study
May 2025 | Volume 24 | Issue 5 | Original Article | 516 | Copyright © May 2025
Background: Treatment of acne may require many months of treatment before maximal benefits are observed, and acne sequelae (eg, scarring, dyspigmentation) can persist long a...
Read MoreAlopecia as an Adverse Event of Immune Checkpoint Inhibitor Therapies: Clinical Evidence and Outcomes
March 2025 | Volume 24 | Issue 3 | Original Article | 255 | Copyright © March 2025
Immunotherapy utilizing immune checkpoint inhibitors (ICIs) such as PD-1, PD-L1, and CTLA-4 inhibitors has revolutionized cancer therapy by enhancing T cell recognition and attack against cancer ...
Read MoreThe Frequency of Non-Scarring Alopecia in Autoimmune Connective Tissue Diseases
March 2025 | Volume 24 | Issue 3 | Original Article | 246 | Copyright © March 2025
Background: Autoimmune connective tissue diseases (ACTDs) are relatively rare systemic diseases featured by immune dysregulation and often have prominent cutaneous manifestations...
Read MoreDifferentiating and Managing Cutaneous Lupus Erythematosus-Associated Alopecia and Patchy Alopecia Areata: Therapeutic Insights From Case Studies
March 2025 | Volume 24 | Issue 3 | Case Reports | 324 | Copyright © March 2025
Cutaneous lupus erythematosus (CLE) is an autoimmune disease with diverse clinical manifestations, including patchy hair lossresembling alopecia areata (AA). This report describes tw...
Read MoreInsights Into Demographics, Comorbidities, and Risk Factors in Keloids and Hypertrophic Scars: A Retrospective Study
February 2025 | Volume 24 | Issue 2 | Features | 212 | Copyright © February 2025
Hypertrophic scars and keloids represent abnormal wound healing, manifesting as raised scars confined to or extending beyond the wound margin, respectively. Understanding the risk factors associated w...
Read MoreA Review of Management Strategies for Erosive Pustular Dermatosis of the Scalp
February 2025 | Volume 24 | Issue 2 | Features | 217 | Copyright © February 2025
© 2026 Journal of Drugs in Dermatology. All Rights Reserved. JDD, a peer-reviewed, MEDLINE®/PubMed® indexed journal, offers the dermatology community strong content of utmost quality and relevance on drugs, devices, and methods.
